Chronic myeloid leukemia

Current Opinion in Hematology

Volumn 5, Issue 4, 1998, Pages 302-308

  Deininger, Michael W N ^b   Goldman, John M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE;

APOPTOSIS; AUTOGRAFT; CHRONIC MYELOID LEUKEMIA; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0032413490     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199807000-00010     Document Type: Review

References (72)

1. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al.: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996, 88:2410-2414.
2. Wilson G, Frost L, Goodeve A, Vandenberghe E, Peake I, Reilly J: BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia [letter]. Blood 1997, 89:3064.
3. Mittre H, Leymarie P, Macro M, Leporrier M: A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease? [letter]. Blood 1997, 89:4239.
4. Yamagata T, Mitani K, Kanda Y, Yazaki Y, Hirai H: Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia. Br J Haematol 1996, 94:370-372.
5. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996, 88:2375-2384.
6. McWhirter JR, Wang JY: Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene 1997, 15:1625-1634.
7. van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC: p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996, 87:5213-5217.
8. Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, et al.: Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996, 87:1075-1080.
9. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, et al.: Interaction between ATM protein and C-Abl in response to DNA damage [see comments]. Nature 1997, 387:520-523.
10. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, et al.: Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation [see comments]. Nature 1997, 387:516-519.
11. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D: Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci U S A 1997, 94:1437-1440.
12. Yuan ZM, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S, Kufe D: Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996, 382:272-274.
13. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF: Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987, 328:342-344.
14. Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bhatia R: Integrin-mediated regulation of hematopoiesis. Do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol 1997, 97:40-52.
15. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY: Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A 1996, 93:15174-15179.
16. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM: Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function [see comments]. J Clin Invest 1994, 94:384-391.
17. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994, 13:764-773.
18. Cortez D, Stoica G, Pierce JH, Pendergast AM: The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 1996, 13:2589-2594.
19. Sanchez Garcia I, Martin Zanca D: Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol 1997, 267:225-228.
20. Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF: ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996, 13:2225-2234.
21. Marais R, Light Y, Paterson HF, Marshall CJ: Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 1995, 14:3136-3145.
22. Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria [see comments]. Cell 1996, 87:629-638.
23. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) [see comments]. Cell 1996, 87:619-628.
24. Weissinger EM, Eissner G, Grammer C, Fackler S, Haefner B, Yoon LS, Lu KS, Bazarov A, Sedivy JM, Mischak H, Kolch W: Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells. Mol Cell Biol 1997, 17:3229-3241.
25. Del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of bad through the protein kinase akt. Science 1997, 278:687-689.
26. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
27. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi KC, et al.: Transformation of hematopoietic cells by BCR/ABL requires activation of a Pl-3k/Akt-dependent pathway. EMBO 1997, 16:6151-6161.
28. Wilson Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB: P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 1996, 56:3426-3430.
29. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE: Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 1996, 95:501-507.
30. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY: Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 1995, 91:387-393.
31. Roger R, Issaad C, Pallardy M, Leglise MC, Turhan AG, Bertoglio J, Breard J: BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 1996, 87:1113-1122.
32. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR: Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem 1995, 270:22625-22631.
33. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, et al.: Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 1997, 89:957-964.
34. Wisniewski D, Strife A, Berman E, Clarkson B: c-kit Ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia. Leukemia 1996, 10:229-237.
35. Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, Clarkson B: P62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997, 88:197-204.
36. Yamanashi Y, Baltimore D: Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell 1997, 88:205211.
37. Hallek M, Danhauser Riedl S, Herbst R, Warmuth M, Winkler A, et al.: Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 1996, 94:5-16.
38. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994, 269:22925-22928.
39. Oda A, Miyakawa Y, Druker BJ, lshida A, Ozaki K, Ohashi H, et al.: Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996, 88:4304-4313.
40. Bhat A, Kolibaba K, Oda T, Ohno Jones S, Heaney C, Druker BJ: Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chem 1997, 272:16170-16175.
41. Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S, Druker BJ: Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 1997, 89:297-306.
42. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC: Characterization of primitive subpopulation of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996, 88:2162-2171.
43. Podesta M, Piaggio G, Sessarego M, Pitto A, Benvenuto F, Vassallo F, et al.: Spontaneous exodus of high numbers of normal early progenitor cells (Ph-negative LTC-IC) in the peripheral blood of patients with chronic myeloid leukaemia at the beginning of the disease. Br J Haematol 1997, 97:94-98.
44. Diamond J, Goldman JM, Melo JV: BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. Blood 1995, 85:2171-2175.
45. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC: Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997, 90:64-69.
46. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, et al.: BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996, 87:4770-4779.
47. Bienaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995, 86:3118-3122.
48. Bose S, Deininger MWN, Gora-Tybor J, Goldman JM, Melo JV: The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease. Blood 1998, in press.
49. Pierson BA, Miller JS: CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996, 88:2279-2287.
50. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997, 89:1133-3142.
51. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS: Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996, 87:2476-2485.
52. Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AW, Gordon Smith EC, et al.: Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986, 1:53-66.
53. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]. Blood 1995, 86:2041-2050.
54. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bierke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Anasetti C: Impact of pre-transplant interferon-α on outcome of unrelated donor marrow transplants for chronic myeloid leukemia in first chronic phase. Blood 1997, 90(suppl 1):123a.
55. Savage GD, Goldman JM: Allografting for chronic myeloid leukemia. Curr Opin Hematol 1997, 4:369-376.
56. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group [see comments]. N Engl J Med 1997, 337:223-229.
57. Goldman JM: Optimizing treatment for chronic myeloid leukemia [editorial; comment]. N Engl J Med 1997, 337:270-271.
58. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR: Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996, 125:541-548.
59. Liberato NL, Quaglini S, Barosi G: Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997, 15:2673-2682.
60. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J. Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
61. Deininger M, Goldman JM, Lydon NB, Melo JV: the tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997, 90:3691-3698.
62. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, di Nicola M, Biondi A, Corneo GM, Pelotti D, Pogliani E, Lydon NB: Inhibition of the abl kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1998, 23:380-394.
63. Carroll M, Ohno Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker B: CGP 57148, a Tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947-4952.
64. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myelogenous leukemia. Blood 1997, 89:2623-2634.
65. Zhao RCH, McIvor RS, Griffin JD, Verfaillie CM: Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood 1997, 90:4687-4698.
66. Chalmers EA, Franklin IM, Kelsey SM, Newland AC, Clark RE, Sproul AM, Crotty G, McCann SR, Fielding A, Goldstone AH, Hepplestone A, Watson W, Sharp RA, Tansey P: Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol 1997, 96:627-634.
67. Hughes TP, Grigg A, Szer J, Ho J, Ma D, Dale BM, Green RM, Norman JE, Sage RE, Herrmann R, Cannell P, Schwarer AP, Taylor K, Atkinson K, Arthur C: Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. Br J Haematol 1997, 96:635-640.
68. Carella AM, Cunningham I, Lerma E, Dejana A, Benvenuto F, Podesta M, Celesti L, Chimirri F, Abote M, Vassallo F, Figari O, Parodi C, Sessarego M, Valbonesi M, Carlier P, Prencipe E, Gatti AM, van den Berg D, Hoffman R, Frassoni F: Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 1997, 15:1575-1582.
69. Reiter A, Skladny H, Hochhaus A, Seifarth W, Heimpel H, Bartram CR, Cross NC, Hehlmann R: Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group. Br J Haematol 1997, 97:86-93.
70. Verschraegen CF, Talpaz M, Hirsch Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM: Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 1995, 85:2705-2710.
71. Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB: Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am J Clin Pathol 1996, 106:442-448.
72. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996, 87:1549-1555.